Boehringer Ingelheim

Boehringer Ingelheim is a leading research-driven biopharmaceutical company, creating value through innovation in areas of high unmet medical need.

One of the world’s largest manufacturers of biopharmaceuticals, Boehringer Ingelheim is an industry pioneer and has produced more than 40 commercial biopharmaceuticals. Our contract manufacturing business, Boehringer Ingelheim BioXcellence™ reliably supplies innovative therapies that transform lives, today and for generations to come and creates solutions with its partners to improve patient health through its production network spanning the globe, from Biberach, Germany to Vienna, Austria, Shanghai, China and Boehringer Ingelheim Fremont Inc., in California, United States.

A mammalian cell culture center in the San Francisco Bay Area, Boehringer Ingelheim Fremont, Inc., has more than 600 scientists and specialists committed to research, development, and manufacturing to deliver high quality medicines for patients. Our modern facility offers high flexibility with stainless steel and single-use bioreactors for fed-batch and process intensification technology manufacturing. With the complete range of services, from cell line and strain development, including high expression systems, through process development and large-scale manufacturing, to Fill & Finish we help our customers to turn innovative biologic ideas into commercial reality.

6701 Kaiser Drive
Fremont, CA 94555 US
NEWS
The last week has marked plenty of investment activity in operations, collaborations and PR the last week or two for Ingelheim, Germany-based Boehringer Ingelheim.
Boehringer Ingelheim and OSE Immunotherapeutics signed a collaboration and license deal to jointly develop OSE-172 for myeloid cancers.
Eli Lilly and Company announced top-line data from its Phase III REACH-2 trial of Cyramza (ramucirumab) as a monotherapy second-line treatment for hepatocellular carcinoma (HCC), which is liver cancer.
Giuseppe Ciaramella, formerly chief scientific officer of Moderna Therapeutics’ Valera unit, has left for an unidentified stealth-mode biotech startup.
Becoming a GIP demonstrates the company’s commitment to clinical research sites and their desire to develop a deeper understanding of the needs of sites, and contribute to the development and implementation of solutions.
Another potential treatment for Alzheimer’s disease has been tossed into the rubbish bin.
Under terms of the deal, Boehringer has the option to acquire Autifony’s Kv3.1/3.2 positive modulator platform, which includes the company’s lead compound AUT00206.
Boehringer’s global head of information technology, Michael Schmelmer, will replace Menne on Jan. 1, 2018.
JOBS
IN THE PRESS